Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study assessing MultiTAA T-cell therapy in post-allogeneic hematopoietic stem cell transplant patients with acute myeloid leukemia in both the adjuvant and active disease setting

Next Previous
Trial Profile

A phase II study assessing MultiTAA T-cell therapy in post-allogeneic hematopoietic stem cell transplant patients with acute myeloid leukemia in both the adjuvant and active disease setting

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zedenoleucel (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Marker Cell Therapy

Most Recent Events

  • 17 Mar 2022 According to a Marker Therapeutics Inc media release, enrollment of the first 20 patients of the trial was completed in Q4 2021. Topline readout of Group 2 active disease is anticipated in Q2 2022.
  • 16 Feb 2022 According to a Marker Therapeutics Inc media release, Marker will host a conference call and webcast at 5:00 p.m. EST today to discuss the clinical program updates including this trial , the webcast will be accessible in the Investors section of the Companys website at www.markertherapeutics.com.
  • 19 Aug 2021 According to a Marker Therapeutics Inc media release, the Company received notice of a Product Development Research award from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the adjuvant arm of the study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top